Gen-Probe Invests $50M in PacBio; Companies to Co-Develop Sequencing-Based Diagnostics
June 22, 2010
Gen-Probe Invests $50M in PacBio; Companies to Co-Develop Sequencing-Based Diagnostics
The tests will likely be based on PacBio's "version 2" technology, which is scheduled to launch in 2014, and could be applicable for point-of care diagnostics, a clinical laboratory, or a service center.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PacBio Looks to Raise up to $200M in IPO; Reports $15M Order Backlog
August 24, 2010 / In Sequence - Paired Ends: David Botstein, Hugh Martin
July 24, 2012 / In Sequence - Using PacBio RS, UCSF Team Shows FLT3-ITD Mutations Are a Valid Therapeutic Target in AML
April 18, 2012 / Clinical Sequencing News - Mt. Sinai to Launch Targeted Sequencing-Based Tests on PacBio RS for Autism, other Conditions
November 16, 2011 / Clinical Sequencing News - PacBio Books 7 RS Systems in Q3, Delays Launch of C2 Chemistry, Launches 'Customer Advocacy' Group
November 1, 2011 / In Sequence